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The role of aspirin on the risk of cancers of the upper aerodigestive tract was investigated in the combined data of three Italian case–
control studies, including 965 cases and 1779 hospital controls. The odds ratio was 0.33 for users of X5 years, and 0.51 for X5 years
since first use.
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Data on the role of aspirin on the risk of cancers of the upper
aerodigestive tract are scanty, and mainly related to cancer of the
oesophagus. In two rheumatoid arthritis cohorts from Finland
(Isoma ¨ki et al, 1978) and Sweden (Gridley et al,1 9 9 3 ) ,n os i g n i f i c a n t
association between aspirin use and oesophageal cancer risk was
observed (relative risk (RR)¼0.94 and 1.3, respectively). In a large
prospective study from the American Cancer Society, a significantly
reduced risk of oesophageal cancer (RR¼0.59) was reported in
subjects who used aspirin X16 times per month for at least 1 year,
and the risk reduction was stronger among users for X10 years
(RR¼0.54) (Thun et al, 1993). In the same study, a nonsignificant
increased risk was observed for oral and pharyngeal cancer. In the
cohort of the National Health and Nutrition Examination Survey,
aspirin use was associated with a 90% decreased risk of developing
oesophageal cancer, although the estimate was based on 15 cases
only (Funkhouser and Sharp, 1995). A US population-based case–
control study, including 221 squamous-cell oesophageal cancer and
293 adenocarcinoma cases, found a significant lower risk for current
aspirin users (odds ratio (OR)¼0.49 for squamous-cell and 0.37 for
adenocarcinoma) (Farrow et al, 1998). In a British case–control
study conducted on 159 women with squamous-cell oesophageal
cancer, 10 cases vs 19 controls reported taking aspirin daily for at
least 1 month (crude OR X0.50) (Sharp et al, 2001). In a case–
control study from Greece with 43 squamous-cell cancers and 56
adenocarcinomas of the oesophagus, the OR was nonsignificantly
reduced for ever aspirin use (Garidou et al,1 9 9 6 ) .
The potential role of aspirin use on cancers of the upper
aerodigestive tract was further investigated using data from three
case–control studies conducted in Italy.
PATIENTS AND METHODS
Three hospital-based case–control studies of cancer on the upper
aerodigestive tract were conducted in Italy between 1992 and 2000
to examine alcohol, tobacco, diet, family history and other
environmental factors, covering a total of 1362 cases and 3038
hospital controls (Franceschi et al, 1999; Bosetti et al, 2000;
Talamini et al, 2002).
Controls were from the same hospitals as cases, admitted for a
wide spectrum of acute, non-neoplastic conditions, not related to
smoking, alcohol consumption or long-term modifications of diet;
they were frequency-matched with cases by 5-year age groups, sex
and study centre. To compensate for the rarity of laryngeal cancer
in women, a control-to-case ratio of about 5 was chosen for
women, as opposed to 2 for men. On average, 5% of cases and
controls approached during their hospital stay refused to be
interviewed (Franceschi et al, 1999; Bosetti et al, 2000; Talamini
et al, 2002).
The interview-administered questionnaire included information
on sociodemographic characteristics, anthropometric measures,
lifestyle habits, including tobacco smoking and alcohol drinking, a
validated food frequency section and personal and family medical
history. The information on aspirin intake included indication, age
at first use, frequency and duration of use. Regular use was defined
as use for at least once a week for more than 6 months. To facilitate
recall of use, a comprehensive list of major aspirin-containing
preparations in Italy was supplied.
A total of 965 cases (850 men, 115 women) of the upper
aerodigestive tract cancer (393 oral and pharyngeal, 225 oesopha-
geal and 347 laryngeal cancer) and 1779 (1450 men, 329 women)
controls with information on aspirin use were included in the
present analysis.
ORs and the corresponding 95% confidence intervals (CI) were
estimated using unconditional multiple logistic regression models
(Breslow and Day, 1980), including terms for age, sex, study centre,
years of education (o7, 7–11, X12), alcohol (o14, 14–27, 28–55,
X56 drinks per week, plus a dummy variable for ex-drinkers) and
tobacco consumption (never, ex-smoker, current smoker of o15,
15–24, X25 cigarettes per day).
RESULTS
Table 1 gives the distribution of 965 upper aerodigestive cancer
cases and 1779 controls according to selected measures of aspirin
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yuse. A total of 37 (3.8%) cases vs 87 (4.9%) controls reported
regular aspirin use. Average frequency of use was 5.7 times per
week among cases and 5.6 among controls; 32 cases and 78
controls took aspirin X3 times per week, 27 cases and 57 controls
every day. Indication of use was analgesia for 10 cases and 38
controls, whereas 27 cases and 49 controls took aspirin for
cardiovascular prevention. The multivariate OR for regular use was
0.89 (95% CI 0.56–1.43). The OR decreased to 0.33 (95% CI 0.13–
0.82) for users of X5 years, and was 0.51 (95% CI 0.26–0.99) for
X5 years since first use.
A reduced risk with longer duration of aspirin use was observed
for all sites considered: the ORs for X5 years of use were 0.39 for
oral and pharyngeal, 0.80 oesophageal and 0.09 laryngeal cancer.
Similarly, the ORs for X5 years since first use were 0.26, 0.66 and
0.55 for the three cancer sites, respectively.
DISCUSSION
This study suggests that aspirin may have a beneficial effect on
cancers of the upper aerodigestive tract. Although there is evidence
of a possible protective effect of aspirin on oesophageal cancer
(Bosetti et al, 2002), only scattered epidemiological data exist on
its role on cancer of the oral cavity or larynx (Thun et al, 1993).
A significant reduced risk has been observed particularly for
long-term use and in relation to a longer time since first use. These
time–risk relations are similar to those described for colorectal
cancer (Giovannucci et al, 1995, IARC, 1997; Thun et al, 2002), and
therefore give plausibility to a causal association.
With reference to possible biological mechanisms, aspirin, as
well as other nonsteroidal anti-inflammatory drugs (NSAID), acts
on the arachidonic acid metabolism, blocking the synthesis of
thromboxane, prostacyclin and prostaglandins, which in turn can
influence cell proliferation, and hence cancer growth (Marnett,
1992; Marcus, 1995). A specific target of the protection against
colorectal and other cancers by aspirin and other NSAID is the
inhibition of cyclooxygenase-2, which is important for apoptosis,
and therefore for control of the mechanisms of carcinogenesis
(Featherstone, 1997; Hong and Sporn, 1997; Taketo, 1998a, b;
Smith et al, 2000). The same mechanisms may be responsible for
the favourable action of aspirin on oesophageal cancer and other
cancers of the upper aerodigestive tract (Morgan and Vainio, 1998;
Chan et al, 1999; Zimmermann et al, 1999; Li et al, 2000).
Limitations of our study should be considered that might have
introduced a spurious association between aspirin use and the
reduced risk of upper aerodigestive tract cancers. It is possible in
fact that aspirin use has been affected by early symptoms of the
conditions under study. The evidence of an association with longer
use is, however, reassuring against this bias. Further, some of the
diagnostic categories of the controls may be associated with
increased aspirin use. However, the results were similar when cases
were compared with each of the major diagnostic categories of
controls, thus giving reassurance against potential selection biases.
Another limitation of this study is that, although based on a large
number of cases, it includes a relatively low number of regular
aspirin users, reflecting the pattern of regular aspirin use in Italy.
Among the strengths of the study are the similar catchment areas
for cases and controls, the almost complete participation rate and
the choice of hospitals controls, who are preferable to population
ones with reference to reliability and validity of information on
drug use, since cases and controls are similarly sensitised towards
various aspects of their medical history (Kelly et al, 1990).
Moreover, the risk estimates were adjusted for major risk factors
for cancers of the upper aerodigestive cancer, that is, tobacco
smoking and alcohol drinking, suggesting therefore that the
inverse relation between long-term aspirin use and cancers of
the upper aerodigestive tract is real.
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